Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have previously reported that the
LRRC4
gene, which contains a conserved leucine-rich repeat (LRR) cassette and an immunoglobulin (Ig) IgC2 domain, is associated with glioma suppression both in vitro and in vivo. The present study provides evidence that the conspicuous absence of
LRRC4
in high-grade gliomas directly contributes to the increasing tumor grade. The loss of
LRRC4
in U251 cells is caused by the loss of homozygosity at chromosome 7q32-ter. It was also found that
LRRC4
requires a functional LRR cassette domain to suppress U251 cell proliferation. In the LRR cassette domain, the third LRR motif of the core LRR is found to be indispensable for the function of
LRRC4
. The inhibitory effect of
LRRC4
is accompanied by a decrease in the expression of pERK, pAkt, pNF-kappaBp65, signal transducer and activator of transcription protein-3 (STAT3), and mutant p53, and an increase in the expression of
c-Jun
NH2-terminal kinase (JNK)2 and p-
c-Jun
, suggesting that
LRRC4
plays a major role in suppressing U251 cell proliferation by regulating the extracellular signal-regulated kinase (ERK)/Akt/NF-kappaBp65, STAT3, and JNK2/
c-Jun
pathways. In conclusion,
LRRC4
may act as a novel candidate of tumor suppressor gene. Therefore, the loss of
LRRC4
function may be an important event in the progression of gliomas.
...
PMID:LRRC4, a putative tumor suppressor gene, requires a functional leucine-rich repeat cassette domain to inhibit proliferation of glioma cells in vitro by modulating the extracellular signal-regulated kinase/protein kinase B/nuclear factor-kappaB pathway. 1672 3